Trial Profile
Relationship between temporal biomarker profiling after atrial fibrillation catheter ablation and the atrial fibrillation recurrence and thromboembolic event
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Embolism and thrombosis
- Focus Biomarker; Pharmacodynamics
- 29 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 New trial record